Camille Blériot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Camille Blériot has a total of 391 co-authors. Here are the top co-authors by number of shared publications:
- Florent Ginhoux
Institut Gustave Roussy, U1356 Next Generation Immuno-Oncology research and therapeutic in pediatric and adult cancer, 114 rue Édouard Vaillant, Villejuif, France
60 shared publications - Mathilde Bied
Gustave Roussy, Bâtiment de Médecine Moléculaire, Villejuif, France
41 shared publications - Jean-Yves Scoazec
Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France
39 shared publications - Kevin Mulder
INSERM U1015, Gustave Roussy, Paris-Saclay University, Villejuif, France
39 shared publications - Nicolas Signolle
Experimental and Translational Pathology Platform, AMMICa, INSERM US23/UAR3655, Gustave Roussy, Villejuif, France
38 shared publications - Charles-Antoine Dutertre
INSERM U1015, Gustave Roussy, Paris-Saclay University, Villejuif, France
34 shared publications
Latest Publications
- Open Access
- 12 September 2026
- Published by Elsevier in JHEP Reports
Immune metabolic reprogramming in MASLD
- 12 September 2026
- Published by Elsevier in JHEP Reports
Open AccessImmune metabolic reprogramming in MASLD
- 25 August 2026
- Published by Elsevier in Cell Metabolism
- Vol. 38 (10) , 2018-2035.e6
Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes
- 25 August 2026
- Published by Elsevier in Cell Metabolism
- Vol. 38 (10) , 2018-2035.e6
Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Representative video of an isolated MGC in oral cavity SCC from GR cohort
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Representative video of an isolated MGC in oral cavity SCC from GR cohort
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Videos Legends from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Legends of the two videos S1 and S2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Videos Legends from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Legends of the two videos S1 and S2
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1 to S7 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Clinical Tables and Statistical Analyses
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1 to S7 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Clinical Tables and Statistical Analyses
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
CosMx 64-plex human immuno-oncology protein panel
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
CosMx 64-plex human immuno-oncology protein panel
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Association between keratin, MGC and clinical outcome
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Association between keratin, MGC and clinical outcome
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Microscopic visualization of MGC
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Microscopic visualization of MGC
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Performances of the deep-learning cell detection model in TCGA cohorts (oral cavity, uterine cervix and larynx SCC) and GR cohorts (oral cavity SCC)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Performances of the deep-learning cell detection model in TCGA cohorts (oral cavity, uterine cervix and larynx SCC) and GR cohorts (oral cavity SCC)